Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GLSI 
Greenwich Lifesciences Inc (GLSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: GLSI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $45
1 Year Target Price $45
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.66% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 114.90M USD | Price to earnings Ratio - | 1Y Target Price 45 |
Price to earnings Ratio - | 1Y Target Price 45 | ||
Volume (30-day avg) 1 | Beta 3.1 | 52 Weeks Range 8.02 - 15.47 | Updated Date 11/4/2025 |
52 Weeks Range 8.02 - 15.47 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.37 |
Earnings Date
Report Date 2025-11-10 | When - | Estimate -0.23 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -219.03% | Return on Equity (TTM) -491.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 142037136 | Price to Sales(TTM) - |
Enterprise Value 142037136 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -21.23 | Shares Outstanding 13630257 | Shares Floating 6374462 |
Shares Outstanding 13630257 | Shares Floating 6374462 | ||
Percent Insiders 51.3 | Percent Institutions 10.6 |
Upturn AI SWOT
Greenwich Lifesciences Inc
Company Overview
History and Background
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences. Founded to commercialize research from Baylor College of Medicine.
Core Business Areas
- GP2 Immunotherapy Development: Focuses on the development and clinical trials of GP2, a HER2/neu peptide immunotherapy for breast cancer.
Leadership and Structure
The leadership team includes Snehal Patel (CEO) and Jaye Thompson (CFO). The company has a relatively small team and relies on contract research organizations (CROs) for clinical trial execution.
Top Products and Market Share
Key Offerings
- GP2: GP2 is an immunotherapy designed to prevent the recurrence of breast cancer in patients who have previously undergone surgery and adjuvant treatment. It targets HER2/neu-expressing cancer cells. Currently, GP2 is undergoing Phase III clinical trials. It is not approved for sale, so no current market share or revenue exists. Competitors depend on future success of GP2.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated. Focus on cancer therapeutics is a significant area of research and development.
Positioning
Greenwich LifeSciences is a relatively small player focused on a niche area within breast cancer treatment, specifically recurrence prevention. Its competitive advantage depends on the success of GP2 in clinical trials.
Total Addressable Market (TAM)
The global breast cancer therapeutics market is substantial (estimated in the tens of billions USD annually). Greenwich's TAM focuses on the HER2-positive breast cancer recurrence prevention segment, depending on GP2's success.
Upturn SWOT Analysis
Strengths
- Focused on a specific unmet need in breast cancer treatment
- Potential for a novel immunotherapy approach
- Strong scientific foundation based on Baylor College of Medicine research
Weaknesses
- Reliance on a single product candidate (GP2)
- Limited financial resources
- Clinical trial risk and regulatory hurdles
Opportunities
- Positive clinical trial results could lead to rapid approval and commercialization
- Partnerships with larger pharmaceutical companies
- Expansion into other HER2-expressing cancers
Threats
- Failure of clinical trials
- Competition from established pharmaceutical companies
- Regulatory delays or rejection
- Adverse events during clinical trials.
Competitors and Market Share
Key Competitors
- SNY
- NVS
- PFE
- MRK
- BMY
Competitive Landscape
Greenwich LifeSciences faces intense competition from established pharmaceutical companies with significant resources and approved breast cancer therapies. Its success depends on demonstrating a superior clinical profile for GP2.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is pre-revenue.
Future Projections: Future growth is entirely dependent on the success of GP2 and potential partnerships.
Recent Initiatives: The primary initiative is the execution of the Phase III clinical trial for GP2.
Summary
Greenwich LifeSciences is a high-risk, high-reward investment. Success hinges on GP2's clinical trial outcomes. The company operates in a competitive landscape against industry giants. Positive results could yield significant returns, while failure carries substantial risk.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Market research reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in biopharmaceutical companies involves significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Greenwich Lifesciences Inc
Exchange NASDAQ | Headquaters Stafford, TX, United States | ||
IPO Launch date 2020-09-25 | CEO, CFO & Director Mr. Snehal S. Patel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | |
Full time employees 4 | |||
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.